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Neurobiology of Disease
APP Regulates Microglial Phenotype in a Mouse Model of
Alzheimer’s Disease
XGunjan D. Manocha,1 Angela M. Floden,1 XKeiko Rausch,1 XJoshua A. Kulas,1 XBrett A. McGregor,1
Lalida Rojanathammanee,2 XKelley R. Puig,1 Kendra L. Puig,1 XSanjib Karki,3Michael R. Nichols,3
XDiane C. Darland,4 James E. Porter,1 and Colin K. Combs1
1Department of Biomedical Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota 58203, 2Institute of
Science, Suranaree University of Technology, Nakhon Ratchasima, 30000 Thailand, 3Department of Chemistry and Biochemistry, University of Missouri-St.
Louis, St. Louis, Missouri 63121-4400, and 4Department of Biology, University of North Dakota, Grand Forks, North Dakota 58202
Prior work suggests that amyloid precursor protein (APP) can function as a proinflammatory receptor on immune cells, such as mono-
cytes andmicroglia. Therefore, we hypothesized that APP serves this function inmicroglia duringAlzheimer’s disease. Although fibrillar
amyloid  (A)-stimulated cytokine secretion from both wild-type and APP knock-out (mAPP/) microglial cultures, oligomeric A
was unable to stimulate increased secretion from mAPP/ cells. This was consistent with an ability of oligomeric A to bind APP.
Similarly, intracerebroventricular infusions of oligomeric A produced less microgliosis in mAPP/ mice compared with wild-type
mice. The mAPP/ mice crossed to an APP/PS1 transgenic mouse line demonstrated reduced microgliosis and cytokine levels and
improved memory compared with wild-type mice despite robust fibrillar A plaque deposition. These data define a novel function for
microglial APP in regulating their ability to acquire a proinflammatory phenotype during disease.
Key words: Alzheimer’s disease; amyloid  oligomers; amyloid precursor protein; microglia; neuroinflammation
Introduction
Amyloid precursor protein (APP) is a type I integral membrane
protein that undergoes proteolysis via amyloidogenic or
nonamyloidogenic pathways (Esch et al., 1990; Shoji et al., 1992;
Haass and Selkoe, 1993; Haass et al., 1993; Jarrett et al., 1993).
Amyloidogenic processing of APP leads to production of amyloid
 (A) peptide, which can undergo self-aggregation, particularly
in the brains of Alzheimer’s disease (AD) patients (Glenner and
Wong, 1984; Masters et al., 1985). Although much interest fo-
cuses on the production and consequences of A peptide, it is
likely that APP has a broader role in both normal and disease
conditions than simply being the parent protein of A peptide.
APP is expressed in numerous tissues apart from the brain.
including the spleen, liver, skin, intestine, kidney, adipose tissue,
heart, muscle, and thymus (Selkoe et al., 1988; Joachim et al.,
1989; Yamada et al., 1989; Sandbrink et al., 1994; Akaaboune et
al., 2000; Herzog et al., 2004; Galloway et al., 2007; Lee et al.,
2008). We and others have also demonstrated that APP is ex-
pressed in immune cells, where it has a role in regulating cellular
phenotype (Mo¨nning et al., 1992; Bullido et al., 1996; Sondag and
Combs, 2004; Vehmas et al., 2004; Carrano and Das, 2015). For
instance, expression on monocytic lineage cells modulates their
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Significance Statement
A hallmark of Alzheimer’s disease (AD) brains is the accumulation of amyloid  (A) peptide within plaques robustly invested
with reactivemicroglia. This supports the notion that A stimulation ofmicroglial activation is one source of brain inflammatory
changes during disease. A is a cleavage product of the ubiquitously expressed amyloid precursor protein (APP) and is able to
self-associate intoawidevarietyofdifferently sizedandstructurallydistinctmultimers. In this study,wedemonstrateboth in vitro
and in vivo that nonfibrillar, oligomeric forms of A are able to interact with the parent APP protein to stimulate microglial
activation. This provides a mechanism by which metabolism of APP results in possible autocrine or paracrine A production to
drive the microgliosis associated with AD brains.
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ability to interact with extracellular matrix and mediates various
cell–cell interactions (Small et al., 1992; Beher et al., 1996; Soba et
al., 2005). TheN-terminal crystalline structure of APP is reminis-
cent of a cell-surface receptor with many putative ligands already
identified (Rossjohn et al., 1999) and the C terminus contains a
well defined YENPTY cytoplasmic signaling motif (Borg et al.,
1996). In addition, APP levels increase in both microglia and
macrophages in a reactive, stimulatory environment (Bauer et al.,
1991) and direct stimulation of APP with agonist antibody leads
to robust activation of microglia/monocytes (Sondag and
Combs, 2004, 2010; Austin et al., 2009). Collectively, these data
suggest that APP serves as a cell-surface receptor regulating mi-
croglial activation.
One putative ligand mediating APP-dependent activation of
these cells is the A peptide itself (Chung et al., 1999; Lorenzo et
al., 2000; Wagner et al., 2000; Van Nostrand et al., 2002; Lu et al.,
2003). Numerous studies have documented an ability of A pep-
tide, in a range of multimeric states, to stimulate microglia to
acquire a reactive phenotype (Combs et al., 1999, 2000, 2001a,b;
Walsh et al., 2002; Sondag et al., 2009; Dhawan andCombs, 2012;
Dhawan et al., 2012). In fact, A plaque-associated reactive mi-
crogliosis is a characteristic change in both rodent models of AD
and human cases (Perlmutter et al., 1990;Wisniewski et al., 1992;
Combs et al., 1999). To test the hypothesis that APP has a role in
regulatingmicroglial response toApeptide,wecomparedA stim-
ulation of wild-type (WT) versus APP knock-out (mAPP/) mi-
croglia in vitro and in vivo following intracerebroventricular
infusion. In addition,we comparedmicrogliosis, cytokine levels, be-
havior, andplaquedeposition in vivo inanAPP/PS1mousemodelof
AD crossed to mAPP/ mice. Collectively, our findings demon-
strate that APP expression is required formicroglial activation, par-
ticularly in response to oligomeric forms of A.
Materials andMethods
Animals. APP/PS1 transgenic mice [strain 005864 B6.Cg-Tg (APPswe,
PSEN1dE9)85Dbo/Mmjax], APP knock-out mice (mAPP/), andWT
mice (C57BL/6) were obtained from the Jackson Laboratory. APP/PS1
express the Swedishmutation in APP andE9mutation in the PS1 gene,
resulting in expression of human APP and secretion of human A. APP/
PS1 mice were bred with mAPP/ mice and the offspring were geno-
typed. Mice positive for the APP/PS1 transgenes were further bred with
mAPP/ mice for multiple generations to knock down mouse APP
completely. TheAPP/PS1mAPP/mice, therefore, express the trans-
genes but lack mouse APP. Males from all four strains of mice [C57BL/6
(WT), APP/PS1,mAPP/, andAPP/PS1mAPP/]were collected at
10months of age for behavioral, histochemical, and biochemical analyses
and 6–7 months of age for mRNA analysis.
Animal use. All animal use was approved by the University of North
Dakota Institutional Animal Care and Use Committee Protocols 1505-4
and 0712-1C.Mice were provided food and water ad libitum and housed
in a 12 h light/dark cycle. The investigation conforms to the National
Research Council of the National Academies Guide for the Care and Use
of Laboratory Animals (eighth edition).
Antibodies and reagents. Anti-A clones 6E10 and 4G8 and rodent-
specific anti-A antibodywere purchased fromCovance, whileMOAB-2
was from Cayman Chemical. Anti-phosphotyrosine (4G10) antibody
was obtained from EMD Millipore. The horseradish peroxidase-con-
jugated secondary antibodies were purchased from Santa Cruz Biotech-
nology. Mouse TNF- ELISA kits were obtained from R&D Systems,
while mouse A 1-40 and A 1-42 ELISA kits were obtained from Ther-
moFisher Scientific. Elite Vectastain ABC avidin and biotin kits, biotin-
ylated anti-rabbit, anti-mouse, and anti-rat antibodies, and the Vector
VIP kits were from Vector Laboratories. Anti-CD68 was obtained from
Serotec. Anti-PSD95 antibody was purchased from Cell Signaling Tech-
nology. Anti-APP antibody was purchased from Invitrogen. Synapto-
physin and III tubulin antibodies were purchased from Millipore
Bioscience Research Reagents. Anti-Iba-1 antibody was from Wako
Chemicals. Anti-APP (Y188), TNF-, and CD11b antibodies were pur-
chased from Abcam. A mixture of three N-terminal APP antibodies ob-
tained from EMD Millipore (22C11 clone and N-terminus anti-APP
rabbit polyclonal antibody) and Abcam (rabbit polyclonal antibody to
APP) was used for the binding assay. The human APP plasmid (pCAX
APP 695) was a gift from Dennis Selkoe and Tracy Young-Pearse (Add-
gene plasmid #30137; Young-Pearse et al., 2007) and the pCMV-RFP
plasmid was a gift from Dr. Saobo Lei and Nicholas Cilz.
Preparation of peptides. A1-42 was purchased from Bachem or
American Peptide for fibril and oligomer preparations, respectively.
Fluorescein-labeled A was purchased from rPeptide for FITC-labeled
A oligomer preparation. Oligomers were generated from a modifica-
tion as described by Chromy et al. (2003). A1-42 peptide was dissolved
in 1:1 acetonitrile/water, aliquoted, and dried. The aliquoted peptides
were stored at 20°C until use. For oligomer preparation, aliquoted
peptidewas dissolved in 50l of hexafluoroisopropanol and then diluted
with 175l of sterile water and stirred at room temperature for 48 h. The
peptide was then spun at 14,000 rpm for 10 min and the supernatant
quantified using the method of Bradford (1976). For A fibril prepara-
tions, A1-42 peptidewas dissolved in deionizedwater and incubated for
a week at 37°C.
Primary microglia and astrocyte cell culture.Microglia were derived as de-
scribed previously (Floden et al., 2005) from the brains of postnatal day 0–3
mice. Meninges-free cortices were removed, trypsinized, and triturated in
microglia media [DMEM/F12 media containing L-glutamine (Invitrogen)
and 20% heat-inactivated FBS] and placed in T-75 flasks. The media in the
flaskswas replacedafter24handpartially after7dwith freshmedia.Thecells
were harvested on day 14. Flasks were shaken for 30 min on a reciprocal
shaker to obtainmicroglial cells. Adherent astrocytes were harvested using a
1mM EDTA solution.
Primary neuron culture. Neurons were cultured from cortices of em-
bryonic day (E) 16mice (C57BL/6).Meninges-free corticeswere isolated,
trypsinized, and plated onto 0.05 mg/ml poly-L-lysine-coated tissue cul-
ture wells (260 cells/mm2) for 14 d in vitro before use. Neurons were
grown in Neurobasal media with glutamine and B27 supplements (Life
Technologies).
Human microglia culture. Human microglia cells were obtained from
Sciencell and maintained in complete microglia media supplemented
with microglia growth medium, penicillin/streptomycin, and fetal bo-
vine serum on poly-L-lysine-coated cell culture plates.
GripTite 293 MSR cell line. For binding assays, GripTite 293MSR cells
(GripTite cells) were purchased fromThermoFisher Scientific andmain-
tained in DMEM/F12 media supplemented with 20% heat-inactivated
FBS and 1% Geneticin antibiotic.
THP-1 cell APP siRNA knockdown. Human monocytic THP-1 cells
were purchased fromATCC and grown as in our prior work (Sondag and
Combs, 2004). APP siRNA knockdownwas also performed as previously
described (Sondag and Combs, 2004). Briefly, THP-1 cells were trans-
fected with APP siRNA (2 106 cells; 2 g of siRNA) using the appro-
priate Nucleofector program as described by themanufacturer (Amaxa).
Cells were transfected with APP siRNA (siGene, SMARTpool Plus) ob-
tained from Dharmacon and used 24 h after transfection or lysed to
determine APP expression.
Cell stimulation. Microglia or THP-1 cells were placed in serum-free
DMEM/F12 media for stimulations with A oligomers or fibrils. Cells
were stimulated with oligomers or fibrils for 5 min or 24 h and harvested
forWestern blotting analyses or ELISA, respectively. For ELISA analysis,
cells were stimulated in 96-well plates (20,000 cells/well, 75 l of serum-
free DMEM/F12) for 24 h with 8 replicates per condition repeated five
independent times. Stimulation experiments for Western blot analyses
were performed for 5 min. After stimulation, cells were lysed in RIPA
buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 1 mM Na3VO4, 10 mM NaF, 1
mM EDTA, 1 mM EGTA, 0.2 mM phenylmethylsulfonyl fluoride, 1%
Triton X-100, 0.1% SDS, and 0.5% deoxycholate) and quantified from
five independent experiments.
Western blot analysis of cell lysates. Lysates were diluted in sample buf-
fer and separated via 10% SDS-PAGE, transferred to polyvinylidene
difluoride membranes, and Western blotted using anti-p-Tyr (4G10),
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anti-APP (Y188), and anti-A (6E10) antibodies using anti-ERK-2,
-tubulin, and GAPDH as the loading controls and enhanced chemilu-
minescence for detection (GE Healthcare). Optical densities (O.D.s)
from visualizedWestern blots was normalized to their respective loading
controls wherever necessary and averaged from three to five independent
experiments.
ELISA from microglia cultures. To assess the level of the proinflamma-
tory cytokine TNF- secreted after 24 h stimulation ofmicroglia with A
oligomers or fibrils, the media from the cells were collected and analyzed
using a commercially available ELISA kit (R&D Systems) according to
the manufacturer’s protocol.
Intracerebroventricular infusion of A1-42 oligomers. WT (C57BL/6)
mice and mAPP/ mice were infused with A oligomer intracere-
broventricularly at 6 months of age as previously described (Dhawan et
al., 2012). Briefly, mice were anesthetized with sodium pentobarbital
(Nembutal, 70 mg/kg). An Alzet (model 1004; 0.25 l/h delivery rate)
osmotic pump was placed in the subscapular region with a cannula
(brain infusion kit, Alzet) stereotaxically placed into the right lateral
cerebral ventricle at coordinates 1.0 mm mediolateral and 0.5 mm
anterioposterior from bregma,1.5 mm dorsal–ventral from skull. The
cannulas were connected to miniosmotic pumps (Alzet, model 1004)
that were then placed subscapularly. The pumps delivered A oligomer
(1.2 g/d) or vehicle (4 mM HEPES, 250 g/ml human high-density
lipoprotein; controls) for 14 d. At the end of the infusion period, mice
were transcardially perfusedwith PBS-CaCl2 and brains rapidly dissected
out. The right hemispheres were collected for cryosectioning and placed
in 4% paraformaldehyde for 72 h, replaced by two cycles of 30% sucrose
for a period of 1 week. The left hemispheres were further dissected into
frontal cortex, temporal cortex, hippocampus, and cerebellum. The tis-
sue was flash frozen in liquid nitrogen and lysed in RIPA buffer for
biochemical analysis.
Immunostaining mouse brains. The paraformaldehyde-fixed right
hemispheres for A oligomer-infused mice (WT and mAPP/), their
respective controls, and 10-month-old mice from four genotypes (WT,
mAPP/, APP/PS1, and APP/PS1mAPP/) were cut using a freez-
ing microtome. Briefly, paraformaldehyde-fixed tissue was embedded in
a 15% gelatin (in 0.1 M phosphate buffer) matrix and immersed in a 4%
paraformaldehyde solution for 2 d to harden the gelatin matrix. The
blocks were then cryoprotected through three cycles of 30% sucrose for
3–4 d each. The blocks were then flash frozen using dry-ice/isomethyl-
pentane, and 40 m serial sections were cut using a freezing microtome.
Serial sections (separated by a 240 m gap) were immunostained using
anti-pTyr (4G10) and anti-A (4G8) antibodies at a dilution of 1:1000 or
anti-CD68, anti-CD11b, and anti-Iba-1 antibodies at a dilution of 1:500
followed by incubation with biotinylated secondary antibodies (1:2000
dilution; Vector Laboratories) and avidin/biotin solution (Vector ABC
kit). Immunoreactivity was visualized using Vector VIP as chromogen.
The slides were dehydrated and coverslipped using VectaMount (Vector
Laboratories) following a standard dehydrating procedure through a se-
ries of ethanol concentrations and Histo-Clear (National Diagnostics).
Images were taken using an upright Leica DM1000microscope and Leica
DF320 digital camera system. Quantitation of immunostaining was per-
formed as previously described (Dhawan et al., 2012). Briefly, optical
densities from the temporal cortex and CA1 regions from the same serial
sections were measured using Adobe Photoshop software (Adobe Sys-
tems). The values for each section were averaged (3 sections/brain, 6–7
brains per condition) and plotted.
Design-based stereological quantification of Iba-1-positive cells.
Paraformaldehyde-imbedded sections from 10-month-old mice from
four genotypes (WT, mAPP/, APP/PS1, and APP/PS1mAPP/)
were cut at 40m intervals and immunolabeled for Iba-1. Sections from
three different mice for each genotype of mice were assessed for Iba-1-
positive nuclei with the section interval set at 960 m. Nonbiased quan-
tification of Iba-1-positive nuclei was conducted using the optical
fractionator method originally developed by West and colleagues (West
and Gundersen, 1990) and adapted from previous studies with other
neural populations (Sharma et al., 2012; Cain et al., 2014). Iba-1-positive
cells in the temporal cortex layerwere counted in every 24th section using
StereoInvestigator 11.06.2 (Microbrightfield) on an Olympus BX51WI
equipped with a motorized x, y, and z stage. In each animal, Iba-1-
positive cells were counted from 21 to 30 randomly and systematically
selected frames in every serial section using the 40 objective. For cell
counting, the contour of the temporal cortex with a pial surface buffer of
100 m was delineated with 2 magnification based on standard ana-
tomical markers and the grid size set following subsampling optimiza-
tion. In brief, the number and location of counting frames and the
counting depth for that section were determined by entering parameters
for the grid size (500 500m), the thickness of top guard zone (2m),
and the optical dissector height (26 m). The guard zones were set at 2
m above and below the counting depth for each section with regional
thickness and variation in section integrity taken into consideration and
the maximum andminimum z depth determined at each sampling loca-
tion before counting. The optimal counting frame width (250 m) and
height (175 m) were determined with an initial oversampling of a rep-
resentative set of sections from control and treated samples. The cell
bodies of the Iba-1-positive cells were counted if theywere entirelywithin
the 26 m depth of the counting frame and only at the z depth at which
the nucleus was in focus. The StereoInvestigator software calculated the
total number of Iba-1-positive cells in the temporal cortex using the 3D
optical fractionator formula designated: N  t/h  1/ssf  1/asf 
1/hsf Q. For the calculations, t/h is the section mounted thickness
over the counting frame height; ssf is the section sampling fraction; asf is
the area sampling fraction, which was calculated by dividing the area
sampled with total area of the temporal cortex (in our tracings, the sum
of temporal cortex areas sampled in every 24th section); hsf is the height
sampling fraction, which was determined by dividing the height of the
counting frame (26 m) by the section thickness determined for each
sampling site (37–39 m on average); and Q denotes the total count
of particles sampled for the entire temporal cortex. The sampling was
optimized for maximal efficiency, with a final mean coefficient of error
(West and Gundersen, 1990) Gundersen of 10% for all sections sam-
pled. One-way ANOVA (GraphPad Prism, 6.0c) was used to analyze
positive nuclei and all data are presented as mean  SEM for n  3
samples.
Western blot analyses of mouse brains. Flash-frozen tissue from differ-
ent brain regions of infusion experiment mice as well as age-matched
four genotypes were lysed, sonicated in RIPA buffer, and quantitated
using the Bradford method (Bradford, 1976). The lysates were resolved
by SDS-PAGE and transferred to polyvinylidene difluoride membranes
for Western blotting using anti-pTyr (4G10), anti-APP (Y188), anti-A
(6E10), anti-A (rodent), anti-GFAP, anti-Iba-1, anti-PSD95, anti-
synaptophysin, anti-syntaxin, anti-TNF-, and anti-CD68 antibodies
with -tubulin as the loading control. Antibody binding was detected
using enhanced chemiluminescence for detection. Western blots were
quantified using Adobe Photoshop software. Optical density (O.D.) of
bands were normalized against their respective loading controls and av-
eraged (SEM).
Thioflavin staining.Mouse brain sections from four genotype animals
were stained with thioflavin (0.1 g/10 ml). To quench lipofuscin auto-
fluorescence, the sections were then incubated in 0.1% Sudan black for
30 min, rinsed with PBS, and coverslipped using PBS/glycerol (1:1).
Tmaze.To assess theworkingmemory of themice, T-maze (Stoelting)
analysis was performed on the four strains of mice as described byWenk
(2001).Mice were placed individually into the starting arm, and the door
was raised to allow animals to walk down the stem and choose an arm.
Once themice entered an armwith all four feet, they were returned to the
starting arm and the doorwas closed. After 30 s, the doorwas opened and
the mice were allowed to choose an arm again. The process was repeated
for nine trials with a 30 s interval between each trial. The choice of arms
was noted each time and the number of alternations between trials for
each mouse was averaged and plotted.
Open-field test. The open-field (Stoelting) test was used to evaluate
locomotor activity and anxiety of themice.Micewere placed individually
in the middle of an open-field apparatus placed inside of a larger opaque
wooden box with the four corners of the arena designated as Q1, Q2, Q3,
and Q4. Mice were allowed to explore the open field for 5 min while
horizontal activity reflecting the range of motion was recorded. After
each 5 min session, the open-field apparatus was cleaned and the next
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mousewas tested. Animal behavior was analyzed via ANY-maze software
(Stoelting).
Light–dark box. Light–dark box (Stoelting) testingwas also performed
to assess anxiety in the mice. The light/dark box had two compartments
separated by a wall with an open door between the two chambers. Each
animalwas initially placed in the light compartment and allowed tomove
freely in the apparatus for 5 min. The movement was recorded and ana-
lyzed by ANY-maze software. After each trial, the chambers were cleaned
and next mouse placed for testing.
Migration assay.Microglia (1.0 106) were plated into the serum-free
DMEM/F12-containing upper chamber of a 24-well transwell insert (3
m, Corning) with the bottom chamber with or without 100 ng/ml
mouse MIP-1 (R&D Systems). Cells were allowed to migrate for 6 h,
then the transwell insert was removed and cells migrated through to the
bottom of the well were counted and averaged (SEM).
Phagocytosis assay. Phagocytosis was quantified by measuring the up-
take of Escherichia coli (K-12 strain) BioParticles fluorescein conjugate
(Life Technologies). Briefly, FITC-E. coli BioParticles (0.25 mg/ml) were
incubated with the microglia (2.0  104/well) in 96-well plates for 6 h.
The media were removed and the cells were then rinsed with 0.25 mg/ml
trypan blue in PBS to quench signal from extracellular BioParticles. In-
tracellular fluorescence was read (excitation, 480 nm; emission, 520 nm)
via fluorescent plate reader (Bio-Tek).
Cell-proliferation assay. A 3[4,5-dimethylthiazol-2-yl]-2,5-diphen-
yltetrazolium bromide (MTT) reduction assay was performed to com-
pare proliferation ability of microglia. For assessing proliferation, 2.0
104microglia fromeach of the genotypeswas plated on a 96-well plate for
24 h in the absence or presence of mitogen-enriched media containing
10% FBS/5% HS. The media were removed and 100 g/ml 3 MTT was
added to culture for 4 h at 37°C. Media were aspirated and the reduced
formazan precipitate was dissolved in isopropanol and absorbances were
read at 560/650 nm via plate reader.
ELISA-based A binding assay.Oligomeric and fibrillar A were an-
alyzed for binding ability to APP using a modified ELISA protocol. A
high-binding 96-well plate (R&D Systems) was coated with recombi-
nant human APP (R&D Systems) at a concentration of 1 g/ml over-
night at room temperature. The next day, wells were rinsed using
ELISA wash buffer (R&D Systems) and incubated with varying con-
centrations of oligomeric or fibrillar A (50, 100, 250, 500, and 1000
nM) for 24 h at 4°C. Following A incubation, the wells were rinsed
and incubated with anti-A-specific antibody (MOAB-2) for 2 h fol-
lowed by incubation with biotinylated anti-mouse secondary anti-
body. This was followed by streptavidin-conjugated HRP antibody
incubation and detection using ELISA substrate reagents (R&D Sys-
tems). The plate was then read using a microplate reader (Biotek
Instruments) at 450/550 nm.
Fluorescein-labeled A binding assay. Oligomers prepared using
FITC-labeled A (FITC-Ao) were analyzed for binding to APP using
APP-transfected GripTite 293 MSR cells. Briefly, GripTite cells were
transiently transfected with an APP plasmid and mock transfected using
an RFP-plasmid using Lipofectamine 3000 (ThermoFisher Scientific) as
per themanufacturer’s protocol. APP-transfectedGripTite cells were 4%
paraformaldehyde fixed at 48 h after transfection and immunostained
using anti-N-terminus APP antibody (EMDMillipore) in the absence of
detergent to identify the expression of cell-surface APP protein. Briefly,
fixed APP-transfected GripTite cells were blocked with PBS containing
5% BSA and incubated with anti-N-terminus APP antibody overnight at
4°C followed by incubation with Alexa-488-tagged anti-rabbit secondary
antibody (Invitrogen). The cells were also incubated with only
secondary antibody to confirm positive immunoreactivity with the
APP primary antibody. Immunoreactivity was visualized using a Leica
DMI6000B inverted microscope and a Leica DFC350FX digital camera
(Leica Microsystems). To identify the binding pattern of FITC-Ao 48 h
after transfection, GripTite cells were incubated with varying concentra-
tions of FITC-Ao. Following 15 min incubations, the cells were washed
withDMEM/F12media and fluorescence intensity was obtained by read-
ing the plate using a microplate reader at an excitation at 490 nm and
emission at 525 nm.Cells were then fixedwith 4%paraformaldehyde and
counterstained with DAPI (4	,6-diamidino-2-phenylindole, dihydro-
chloride) and fluorescence intensity of DAPI read at 360/450 nm. Rela-
tive fluorescence units (RFUs) obtained for FITC-Ao were normalized
against RFUs for DAPI, averaged, and plotted (SEM). To understand
the specific binding of FITC-Ao to APP, APP-transfected GripTite cells
were either left unblocked or blocked with a mix of 3 N-terminal APP
antibodies (1 g/ml, each) for 30 min. Cells were then incubated with
FITC-Ao and the binding was determined as mentioned above. To
further validate the binding of Ao to APP, a competition binding assay
was performed using unlabeled Ao. APP-transfected cells were
incubated with increasing concentrations of unlabeled Ao for 30 min
and then competition binding was analyzed by treating the cells with
50 nM FITC-Ao for 15 min. All RFU values were normalized against
DAPI fluorescence intensity and presented as SEM from three inde-
pendent experiments. To calculate equilibrium dissociation constants
for A oligomers, nonlinear regression analysis was performed using
GraphPad Prism version 6.05 for Windows (GraphPad Software,
www.graphpad.com).
Dot blot.Oligomeric and fibrillar A (2g each) were dot blotted onto
polyvinylidene difluoride membranes and incubated with anti-A
(MOAB-2) antibody. Antibody binding was detected using enhanced
chemiluminescence for detection.
Tissue cytokinemRNA real-time PCR and ELISA. Parietal cortices from
6 to 7 months of WT, APP/PS1, mAPP/, and APP/PS1mAPP/
mice were lysed using Qiazol RNA lysis buffer and RNA was isolated
using Qiagen RNeasy Lipid Tissue Kit (Qiagen) according to the manu-
facturer’s protocol. For amplification of mRNA for cytokine markers
(TNF-, IL-6, and IL-10), 150 ng of RNA was used as a template for
performing real-time PCR using the iTaq Universal SYBR Green One-
Step kit (Bio-Rad). Additionally, part of the parietal cortices were lysed in
RIPA buffer and protein levels quantified using the BCA assay. The ly-
sates were used to quantify TNF- levels using a commercially available
ELISA kit (R&D Systems) according to the manufacturer’s protocol.
TNF- concentrations (picograms per milliliter) were calculated per to-
tal protein level in the tissue lysate and plotted (SEM).
Statistical analysis. Data are presented as mean SEM. Values statis-
tically different from controls were determined using one-way ANOVA
(or two-way ANOVA where required). The Tukey–Kramer multiple-
comparisons post-test was used to determine p values.
Results
A oligomer stimulation increased total protein phosphotyrosine
levels and TNF- secretion in microglia and THP-1 cells only
when they expressed APP
To determine whether a particular form of A peptide might
require APP expression for microglia stimulation, preparations
of oligomeric and fibrillar A1-42 were prepared to stimulate
primarymurinemicroglia cultures or the human cell line THP-1.
Oligomeric A separated via SDS-PAGE into a range of molecu-
lar weights from
15 to 55 kDa (Fig. 1A). However, fibrillar A
remained SDS insoluble andunable to enter the resolving portion
of the SDS gel (Fig. 1A). Both oligomeric and fibrillar A stimu-
lated increased protein phosphotyrosine levels in primary THP-1
cultures and microglia (Fig. 1B,C). Fibrillar A was still able to
stimulate a significant increase in protein phosphotyrosine levels
in APP-knockdown THP-1 cells or mAPP/ microglia (Fig.
1B,C). However, oligomeric A had a completely attenuated
ability to stimulate increased tyrosine phosphorylation in the ab-
sence of APP (Fig. 1B,C). To validate that the changes in stimu-
lated tyrosine kinase-associated signaling corresponded to a
change in secretory phenotype, media from WT and mAPP/
microglia were quantified for secreted TNF. As expected, both
oligomeric and fibrillar A stimulated increased TNF secretion
in WT microglia cultures (Fig. 1D). However, the ability of oli-
gomeric but not fibrillar A to stimulate increased TNF secre-
tion was completely attenuated inmAPP/microglia (Fig. 1D).
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Figure 1. A oligomers stimulated increased protein phosphotyrosine levels and TNF- secretion only inmicroglia and THP-1 cells expressing APP. A, A oligomers (Ao) and A fibrils (Af)
were resolved on 15%denaturing polyacrylamide gels andWestern blotted using anti-A (6E10) antibody.B, THP-1 cells were stimulated (5min, 20M)with Ao and Af with orwithout a 24 h
knockdownwith APP siRNA. Cells were lysed and lysates resolved via 10%SDS-PAGE andWestern blotted using anti-phosphotyrosine (4G10) antibody alongwith anti-APP and anti-ERK-2 (loading
control) antibodies. C, Microglia from C57BL/6 (Wild Type) and mAPP/mice were stimulated with vehicle, 20M Ao, or Af for 5 min. Cells were lysed and lysates were separated by 10%
SDS-PAGE and Western blotted with anti-phosphotyrosine (4G10) antibody and anti--tubulin antibody (loading control). Densitometry analysis was performed and fold change in protein
phosphotyrosine levels over control were plotted. D, Microglia fromWT andmAPP/mice were stimulated with Ao and Af for 24 h and secreted TNF- levels were determined using ELISA.
TNF- values were averaged (SEM). Blots and graphs are representative of three independent experiments [*p 0.05, **p 0.01, ***p 0.001 (C, D)].
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Figure 2. A oligomer infusion stimulated increased protein phosphotyrosine levels, increased microgliosis, and decreased neuronal marker proteins in WT but not mAPP/ mice. A
oligomers were infused into the right lateral ventricle of 6-month-old, male C57BL/6 (Wild Type) andmAPP/mice for 14 d. A, Lysates prepared from brain left hemispheres [frontal cortex (FC),
temporal cortex (TC), hippocampus (HP), and cerebellum (CB)] were resolved via 10% SDS-PAGE and Western blotted with anti-phosphotyrosine (4G10), anti-CD68 (microglia marker), neuronal
marker (anti-PSD95, anti-syntaxin, and anti-synaptophysin antibodies), and anti--tubulin (loading control) antibodies. Representative blots of five animals per (Figure legend continues.)
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Intracerebroventricular A oligomers infusion increased total
protein phosphotyrosine levels, increased microgliosis, and
decreased neuronal marker proteins in WT but not mAPP/
mice
To validate the in vitro findings, we next determined whether
oligomeric A could stimulate similar tyrosine kinase-associated
microgliosis in vivo using C57BL/6 (WT) and mAPP/ mice.
The mice were intracerebroventricularly infused with vehicle or
oligomeric A for 14 d as in our priorwork (Dhawan et al., 2012).
As expected, oligomeric A infusion into WT mice stimulated
increased total protein phosphotyrosine (4G10) levels in all four
regions of the brain analyzed: frontal cortex, temporal cortex,
hippocampus, and cerebellum (Fig. 2A,B). Microgliosis, exam-
ined by CD68 protein levels, was also increased in the temporal
cortex, hippocampus, and cerebellum of oligomeric A-infused
mice (Fig. 2A,B). These changes in protein levels correlated with
increased phosphotyrosine and CD68 immunoreactivity as as-
sessed in the hippocampus of the WT infused mice (Fig. 2C). In
agreement with the in vitro findings, oligomeric A infusion into
mAPP/ mice stimulated no increase in phosphotyrosine or
CD68 protein levels or immunoreactivity (Fig. 2A–C). A oli-
gomer infusion intoWTmice also led to a reduction in neuronal
protein markers PSD95, syntaxin, and synaptophysin in several
of the brain regions examined correlating with the microgliosis
(Fig. 2B).
APP/PS1mAPP/mice had limited transgene expression in
microglia and altered A plaque pathology compared with APP/
PS1 mice
The in vitro and infusion findings supported the idea that endog-
enous APP, particularly on microglia, was needed for microglio-
sis in response to oligomeric A stimulation. To further validate
this idea through a genetic strategy, we next crossed an APP/PS1
mouse line mice expressing the human Swedish APP and E9
presenilin 1 (PS1) mutant proteins with mAPP/mice to elim-
inate endogenous mouse APP. To validate the expression of hu-
man or mouse APP, brains of 10-month-old male WT (C57BL/
6), APP/PS1, mAPP/, and the crossed (APP/PS1mAPP/)
mice were examined. Western blotting using anti-APP (Y188)
antibody to measure total APP levels (murine and human) dem-
onstrated a significant increase in the APP/PS1 and APP/
PS1mAPP/ mouse temporal cortices as expected (Fig. 3A).
Also as expected, rodent APP was observed only inWT and APP/
PS1 temporal cortices and was absent in mAPP/ and APP/
PS1mAPP/ mice, demonstrating that the crossed mice
carried only the transgene APP (Fig. 3A). Based upon the over-
expression of APP observed, we compared A plaque pathology
in the four lines. The APP/PS1 mice demonstrated a characteris-
tic plaque load assessed by thioflavin S staining and anti-A
(4G8, BAM10) staining (Fig. 3B,C). However, despite a similar
APP transgene expression, the APP/PS1mAPP/ mice had
decreased thioflavin S and 4G8 staining and nearly completely
attenuated BAM10 A immunoreactivity (Fig. 3B,C). Although
the prion promoter is likely to drive expression in cell types be-
yond neurons in the APP/PS1mAPP/ mice, Western blot
validation ensured that the transgene was not readily detectable
in microglia cultures, suggesting that the brains of these animals,
although highly expressive for mutant APP in neurons, were de-
ficient inmicroglial APP (Fig. 3D). This was further examined by
comparing endogenous levels of APP in cultures of murine neu-
rons, astrocytes, andmicroglia compared with humanmicroglia.
Murine microglial APP protein levels, while present, were re-
duced compared with neurons (Fig. 3E). Human microglia also
expressed APP, demonstrating species conservation (Fig. 3E).
Levels of murine A secreted from microglial cultures were
quantifiedwith no detectable A1-42 (data not shown) and levels
of A1-40 not above the ELISA kit background, since there was
no difference in theA1-40 concentration values betweenmicro-
glia cultures prepared from WT and mAPP/ mice (Fig. 3F).
These data verified that microglia normally express mAPP and
hAPP in mice and humans, respectively, although the mutant
human transgene was not detectably expressed in mouse micro-
glia. Moreover, APP may not be processed to A in these cells.
APP/PS1mAPP/mice had attenuated microgliosis compared
with APP/PS1 mice
To examine whether the absence of APP had the predicted effects
on microgliosis in vivo, we next compared levels of markers for
microglial activation in the 10-month-old male WT, APP/PS1,
mAPP/, and APP/PS1mAPP/ mice. Although CD11b
and Iba-1 are pan-microglia markers, they have been useful in
identifying A plaque-associated microglia in APP/PS1 mice
(Radde et al., 2006; Combs, 2009). In confirmation of this prior
work, we observed increased CD11b and CD68 immunoreactiv-
ity (Fig. 4A), as well as an increased number of Iba-1-positive cells
(Fig. 4B) in these mice compared with WT (C57BL/6) and
mAPP/mice. However, despite the continued presence of A
plaques in the APP/PS1mAPP/mice, they had significantly
lower immunoreactivity and total protein levels of several micro-
glial activation markers, including phosphotyrosine, CD68, and
CD11b levels in the temporal cortex (Fig. 4A,C) and hippocam-
pus (data not shown), indicating that endogenous APP is re-
quired for A plaque-associated microgliosis. The total number
of Iba-1-positive microglia in the temporal cortex of each of the
four genotypes ofmice were estimated using unbiased stereologi-
cal analyses and, as expected, the number of Iba-1-positive mi-
croglia in the APP/PS1mAPP/ mice were also significantly
lower than in the APP/PS1 mice (Fig. 4B).
mAPP/ and APP/PS1mAPP/microglia had reduced
migratory ability
TheAPP/PS1mAPP/mice had attenuatedmicrogliosis despite
thepresenceof significantAplaques.Although this couldbedue to
loss of A-stimulated microglial activation, we also tested the hy-
pothesis that limited microgliosis was related to attenuated micro-
glialmigratory ability. To determinewhethermicroglia lackingAPP
hadanalteredoverall phenotype, primarymicroglia fromWT,APP/
PS1, mAPP/, and APP/PS1mAPP/mice were cultured and
phagocytosis, migration, and proliferation assays were performed.
There were no differences in phagocytosis ability between the four
strains of microglia (Fig. 5A). However, both the mAPP/ and
APP/PS1mAPP/ microglia had significantly attenuated
chemokine-stimulated migratory ability compared with WT and
APP/PS1 mice (Fig. 5B). Surprisingly, both APP/PS1 and APP/
PS1mAPP/ microglia had decreased proliferation compared
with WT and mAPP/mice (Fig. 5C). These data suggested that
the lack of plaque-associated microgliosis in the APP/
PS1mAPP/ mice could be a combination of attenuated re-
4
(Figure legend continued.) group are shown. B, Optical density (O.D.) was measured, aver-
aged, and plotted (SEM; *p 0.05, **p 0.01). C, Right hemispheres of brains were fixed
in 4% paraformaldehyde, sectioned, and immunostained using anti-phosphotyrosine (4G10)
and anti-CD68 antibodies. Representative images (arrows) from five animals per group at 10
magnification are shown from the CA1 region of the hippocampus with inserts at 63magni-
fication. Quantitation of immunostaining was performed and O.D. values were averaged and
plotted (SEM; *p 0.05).
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Figure 3. APP/PS1mAPP/ mice had limited transgene expression in microglia and altered A plaque pathology compared with APP/PS1 mice. A, Temporal cortices from left
brain hemispheres from 10-month-old C57BL/6 [Wild Type (WT)] mice, APP/PS1 mice, mAPP/, and APP/PS1mAPP/mice were lysed and resolved via SDS-PAGE and Western
blotted using anti-APP Y188 (human and rodent specific), anti-A (rodent specific), and-tubulin antibodies (loading control). Optical densities were measured, averaged, and plotted
(SEM). B, Brain sections from 10-month-old C57BL/6 (WT) mice, APP/PS1 mice, mAPP/, and APP/PS1mAPP/mice were paraformaldehyde fixed, sectioned, and immuno-
stained using anti-A (4G8) antibody or stainedwith thioflavin S. Representative images from10 animals per group are shown at 10magnification. Quantitation of immunostaining
was performed and optical density (O.D.) values were averaged and plotted [SEM; *p 0.05, **p 0.01, ***p 0.001 (A, B)]. C, Brain sections from 10-month-old APP/PS1 mice
and APP/PS1mAPP/ mice were also immunostained with anti-BAM10 and anti-A (rodent) antibody. Representative images at 10 magnification are shown with arrows
representing positive immunostaining. D, Microglia from WT, APP/PS1, mAPP/, and APP/PS1mAPP/mice [postnatal day (P) 0 –P3] were cultured. Cells were lysed, resolved
via SDS-PAGE, and Western blotted using anti-APP (Y188) and-tubulin antibodies. E, Primary murine microglia, neuron, astrocyte, and human microglia cell lysates were resolved via
SDS-PAGE andWestern blotted using anti-APP (Y188) and GAPDH antibodies. F, Primary microglia cultures fromWT (C57BL/6) andmAPP/mice were prepared and culture media was
used to perform A1-40 ELISA.
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sponse to A stimulation as well as less chemoattraction toward
plaques.
Oligomeric A interacted with APP in a concentration-dependent
manner
To better validate the possibility of a direct A–APP interaction
as a possible source of microglial activation, the ability of A
oligomers and fibrils to interact with APPwas determined using a
modified ELISAprotocol whereinA bound toAPPwas detected
using an A-selective antibody with no cross-reactivity to APP.
A oligomer interacted with APP in a dose–response manner
whereas fibrillar A failed to bind to APP in levels appreciably
above the assay background (Fig. 6A). These data supported the
notion that a specific interaction between A oligomers and APP
on the microglial surface can drive microgliosis independent
from that stimulated by fibrillar A. To assess any affinity differ-
ences of the anti-A antibodyMOAB-2 for oligomeric and fibril-
lar A, 2 g of prepared peptides (oligomer and fibril) were dot
blotted onto a PVDFmembrane and detected using the antibody.
Figure 4. APP/PS1mAPP/mice had attenuatedmicrogliosis and phosphotyrosine immunoreactivity. A, Brains from 10-month-old C57BL/6 [Wild Type (WT)], APP/PS1, mAPP/, and
APP/PS1mAPP/ mice were collected and right hemispheres fixed in paraformaldehyde. Hemispheres were sectioned and immunostained using anti-phosphotyrosine (4G10), anti-CD68,
and anti-CD11b antibodies. Representative images from 10 animals per group are shown at 10 magnification (insets show 63 magnification). Quantitation of immunostaining was
performed and optical density values were averaged and plotted (SEM). B, Brains from 10-month-old C57BL/6 (Wild Type), APP/PS1, mAPP/, and APP/PS1mAPP/ mice were
immunostained using anti-Iba-1 antibody and Iba-1-positive cells were counted using Stereology Investigator software, averaged, and plotted (SEM; *p 0.05). C, Left brain hemispheres from
10-month-old C57BL/6 (WT), APP/PS1,mAPP/, andAPP/PS1mAPP/micewere further dissected out into hippocampus and temporal cortex and lysed. Lysates from temporal cortexwere
then resolved via SDS-PAGE andWestern blotted using anti-phosphotyrosine (4G10), anti-CD68, anti-PSD95, anti-GFAP, anti-Iba-1, anti-synaptophysin, and anti--tubulin antibodies. Represen-
tative blots from7 animals per group are shown. Optical densities were measured, averaged, and plotted (SEM; *p 0.05, **p 0.01, ***p 0.001).
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As shown in the figure, the anti-A antibody MOAB-2 was able
to recognize both oligomeric and fibrillar A (Fig. 6A, inset). To
further authenticate a direct Ao–APP binding, oligomers pre-
pared from fluorescein-labeled A (FITC-Ao) were used.
FITC-A oligomers were first confirmed to have a similar migra-
tion pattern by SDS-PAGE as the unlabeled A oligomers (Fig.
6B). To perform the binding studies, a humanAPP construct was
expressed in GripTite 293 MSR cells. Cell-surface localization of
APP was confirmed by immunostaining transfected cells with
anti-N-terminal APP antibody in the absence of detergent (Fig.
6C). There was a concentration-dependent increase in RFUs
quantified from APP-transfected cells incubated with FITC-Ao
compared with mock-transfected cells (Fig. 6D), suggesting spe-
cific binding between FITC-Ao and the transfected APP bind-
ing site expressed on GripTite cells. To further confirm the
specific binding and estimate affinity of FITC-Ao for APP, a
mixture of anti-N-terminal APP antibodies was used to define
nonspecific binding. Increasing concentrations of FITC-Ao
specifically labeled a saturable, homogenous, high-affinity bind-
ing site on APP-transfected cells (Fig. 6E). The equilibrium dis-
sociation constant (Kd) of FITC-Ao for this specific APP
binding site was calculated to be 5.3  1.8 nM. To substantiate
this APP binding site as the physiological receptor, unlabeled A
oligomer was used to compete for specific binding sites identified
by FITC-Ao. Increasing concentrations of unlabeled A oli-
gomer decreased the RFUs of bound FITC-Ao with an IC50 of
14.0 2.1 nM (Fig. 6F). Using the method of Cheng and Prusoff
(1973), the equilibrium dissociation constant (Ki) of unlabeled
A oligomer for the specific APP binding site was calculated to be
1.3 0.2 nM.
APP/PS1mAPP/mice had attenuated TNF- and IL-6 levels
Although microgliosis was attenuated in the APP/PS1
mAPP/ mice, microglia are not the only cell type involved in
mediated brain inflammatory changes. To determine whether
the altered microgliosis in APP/PS1mAPP/mice correlated
with attenuated inflammatory changes in the brain, parietal cor-
tices mRNA from WT, APP/PS1, mAPP/, and APP/
PS1mAPP/ mice were analyzed for cytokines using real-
time PCR. Levels of TNF-, IL-6, and IL-10 mRNA were
determined as representative cytokines. Correlating with the re-
duced phosphotyrosine levels andmicrogliosis in the brain, APP/
PS1mAPP/mice had reduced TNF- and IL-6mRNA levels
in the parietal cortex with no significant differences in anti-
inflammatory IL-10 levels compared with APP/PS1 mice (Fig.
7A). Protein levels of TNF- were also reduced in APP/
PS1mAPP/ mice by a fraction similar to that for reduced
mRNA levels (Fig. 7B). These data demonstrated a reduced pro-
inflammatory state in the brains of APP/PS1mAPP/mice.
APP/PS1mAPP/mice had improved memory performance,
increased exploratory behavior, and reduced anxiety compared
with APP/PS1 mice
To determinewhether the loss of APP and the reduced gliosis and
cytokine levels in the APP/PS1mAPP/mice resulted in im-
proved behavioral outcomes, these mice were examined in the
open-field, light/dark box, and T-maze paradigms. Interestingly,
Figure5. Microglial cultures frommAPP/mice andAPP/PS1mAPP/micehad reduced chemokine-inducedmigratory ability comparedwithWTandAPP/PS1mice.Microglia fromWT,
APP/PS1, mAPP/, and APP/PS1mAPP/ mice [postnatal day (P) 0–P3] were cultured to quantify microglial behavior. A, To assess phagocytic ability, microglia were incubated with
fluorescein-conjugated Escherichia coli (K-12 strain) BioParticles for 6 h, then extracellular signal quenched by rinsing with 0.25 mg/ml trypan blue. Intracellular fluorescence was read (excitation,
480 nm; emission, 520 nm) via fluorescent plate reader. B, To compare migration ability, microglia were plated into the upper chamber of transwell inserts and allowed to migrate into the lower
chamber containing 100ng/mlmurineMCP-1 for 6 h. The transwellswere removedand cells that hadmigrated through to thebottomof thewellwere counted andaveraged (SD; ***p0.001).
C, To compare proliferative ability, microglia from each of the genotypes were plated onto a 96-well plate for 24 h in the absence or presence of mitogen-enriched media containing 10% FBS/5%
horse serum. Themedia were removed and 100g/mlMTTwas added to the cultures for 4 h at 37°C. Media were aspirated and the reduced formazan precipitate was dissolved in isopropanol and
absorbances were read at 560/650 nm via plate reader (without serum: *p 0.05, **p 0.01; with serum: #p 0.05, ##p 0.01).
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the compromise in open-field exploratory behavior demon-
strated by the APP/PS1 mice was not present in the APP/
PS1mAPP/ mice (Fig. 8B). However, both APP/PS1 and
APP/PS1mAPP/mice had reduced time spent and explora-
tion in the center of the open field compared with WT mice,
suggesting that both mice shared an anxiety phenotype (Fig. 8B).
To better assess this possibility, performance in the light/dark box
paradigm was examined for each line. The APP/PS1 mice had a
longer latency to the first entry into the dark side of the box,
correlating with less mobility and more overall time spent in the
light portion, compared with the APP/PS1mAPP/ mice
(Fig. 8C). This suggested that the APP/PS1mAPP/mice had
Figure 6. Oligomeric A interacted with APP in a concentration-dependent manner. A, Recombinant human APP-coated plates were incubated with increasing amounts of oligomeric
and fibrillar A and detected using anti-A (MOAB-2 antibody). Optical density (O.D.) values were measured from three independent experiments was averaged and plotted (SEM).
Prepared A (oligomer) and A (fibril) were each dot blotted (2g) onto PVDFmembranes and detected using anti-A antibody MOAB-2 (inset). B, Oligomers prepared from unlabeled
A and FITC-labeled A were prepared and resolved via SDS-PAGE and Western blotted using 6E10 antibody. C, GripTite 293 MSR cells are transfected with APP695 plasmid,
paraformaldehyde fixed, and immunolabeled using N-terminal APP antibody in the absence of detergent to identify cell-surface APP. D, APP-transfected or mock-transfected (RFP)
GripTite cells were incubated with FITC-Ao for 15 min and fluorescence intensity read at 490/525 nm. E, To identify FITC-Ao-specific binding, APP-transfected cells were unblocked
or blocked using a mix of N-terminal APP antibodies for 30 min followed by a 15 min incubation with increasing concentrations of FITC-A oligomer. Cells were washed with DMEM and
the fluorescence read at 490/525 nm. F, Competition binding assay was performed by independently incubating APP-transfected GripTite cells with increasing concentrations of
unlabeled A oligomer for 30 min followed by incubation with 50 nM FITC A oligomer for 15 min. Following measurements of FITC-Ao intensities, all the cells were paraformaldehyde
fixed, counterstained with DAPI, and the fluorescence intensity read at 360/450 nm. Florescence intensity of bound FITC-Ao was normalized against DAPI, averaged, and plotted
(SEM).
Manocha et al. •Microglial Activation Is Regulated by APP J. Neurosci., August 10, 2016 • 36(32):8471–8486 • 8481
decreased anxiety compared with the APP/PS1 mice. Finally, to
examine an AD-relevant behavior, working memory was com-
pared across the mouse lines by recording T-maze alternations.
Although the APP/PS1mice demonstrated the expected decrease
in spontaneous alternations compared with WT mice, the APP/
PS1mAPP/ mice did not (Fig. 8A). The behavioral com-
parisons demonstrated a correlation between our observed de-
crease of gliosis and cytokine expression in the brains of the APP/
PS1mAPP/ mice and improved working memory, reduced
anxiety, and increased exploratory behavior when compared
with the parent APP/PS1 line.
Discussion
Our prior work demonstrated that APP can behave as a proin-
flammatory receptor on monocytic lineage cells mediating ty-
rosine kinase-based activation (Sondag and Combs, 2004).
Therefore, we hypothesized that itmay serve a similar function in
microglia. Primary murine microglia cultures from WT and
mAPP/mice were stimulated with oligomeric or fibrillar A.
Although fibrillar A stimulated increased protein phosphoty-
rosine levels and TNF secretion from both cultures, oligomeric
stimulation of mAPP/microglia was significantly attenuated.
In addition, mAPP/microglia cultures had no attenuation of
phagocytic ability but demonstrated significant impairment in
migratory ability in vitro comparedwithWTmicroglia. Similarly,
intracerebroventricular infusions of oligomericAproduced sig-
nificantly less microgliosis in mAPP/ compared with WT
mice. These findings suggested a role for APP in modulating the
microglial response to selectively oligomeric A and are consis-
tent with our observation that A oligomers bind to APP. We
next crossed mAPP/ mice with mice expressing human mu-
tant APP/PS1 to assess whether absence of murine APP attenu-
ated microgliosis in the presence of accumulations of A
oligomers and fibrils in vivo. The APP/PS1mAPP/mice had
significantly reduced microgliosis despite similar plaque loads
compared with APP/PS1 mice. This correlated with improved
memory performance and decreased anxiety in the APP/
PS1mAPP/ mice. These data define a novel function for
microglial APP in regulating their migratory ability and response
to A peptides, which may be relevant for modulating their be-
havior in AD.
We recognize that A peptide may be secreted from a variety
of cells, including neurons (Busciglio et al., 1993; Walsh et al.,
2000; Takahashi et al., 2004), astrocytes (Siman et al., 1989;Haass
et al., 1991), microglia (Banati et al., 1993b), or even peripheral
cells for transport into the brain (Goldgaber et al., 1989; Farkas et
al., 2003; Austin and Combs, 2010), where it may be responsible
for the microglial activation associated with AD. Our data sup-
port the idea that APP may be able to generate its own ligand,
oligomeric A, capable of regulating microglial phenotype in a
paracrine or even autocrine fashion. This is further supported by
Figure 7. APP/PS1mAPP/mice had attenuated TNF- and IL-6 levels. Parietal cortices from left brain hemispheres from 6–7-month-old C57BL/6 (WT)mice, APP/PS1mice,mAPP/,
andAPP/PS1mAPP/micewere collected formRNA isolation andprotein lysates.A,B, Levels of TNF-, IL-6, and IL-10mRNA (A) andTNF-protein levels (B)weredeterminedusing real-time
PCR and ELISA, respectively. Fold change in the level ofmRNA expression for each groupwas calculated as 2^-Ct with respect to averagemRNA expression of theWT group. The values obtained
for 3–8 animals per group were averaged and plotted (SEM; *p 0.05).
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Figure 8. APP/PS1mAPP/ mice had increased exploratory behavior, reduced anxiety, and improved working memory compared with APP/PS1 mice. A, 10-month-old C57BL/6 (WT),
APP/PS1,mAPP/, andAPP/PS1mAPP/mice (n10per group)were subjected to T-maze testingand thenumber of alternationswere recorded, averaged, andplotted (SD; *p0.05,
**p 0.01, ***p 0.001).B, In addition, the samemicewere subjected to open-field testing. Total distance traveled, timemobile, and time immobile during the 5min trial periodwas averaged
(for10mice per group) and plotted (SD). Total number of entries into the center zone, total time spent in the center zones, and the total distance traveled in the center zonewere averaged and
plotted (SD). Number of entries into each of the four quadrants (Q1, Q2, Q3, and Q4) were noted, averaged, and plotted (SD; *p 0.05, **p 0.01, ***p 0.001). C, Finally, themice were
tested via light/dark box transitions for 5min recording time spent in the light, time immobile in the light, distance traveled, and latency to first dark-side entry. Thedatawere averaged (SD; *p
0.05, **p 0.01, ***p 0.001).
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our observations that oligomeric A directly binds to APP with a
very high affinity and this binding could be prevented by blocking
the cell surface-expressed APP with anti-N-terminal APP anti-
bodies. Our results correlate these specific APP binding sites on
HEK293 GripTite cells with the physiological receptor onmicro-
glia because of the specific, saturable, and high-affinity binding
properties of A on these cells.
Although our in vitro data suggest that oligomeric A inter-
acts directlywithAPPonmicroglia to stimulate a tyrosine kinase-
based activation response, we appreciate that this may not be
occurring in vivo. However, we showed via the acute intracere-
broventricular infusion paradigm that APP expression was
required for the oligomeric infusion to stimulate increased mi-
croglial activation in vivo. In addition, others have shown that
oligomeric A both in vitro (Roher et al., 1996; Lue et al., 1999;
McLean et al., 1999) and in vivo (Cleary et al., 2005; Klyubin et al.,
2005; Lesne´ et al., 2006) stimulate microglial activation, which is
at least consistent with the notion that this form of the peptide is
a disease-relevant ligand. Nevertheless, we (Floden et al., 2005;
Sondag et al., 2009; Dhawan and Combs, 2012; Dhawan et al.,
2012) as well as many others (Banati et al., 1993a; Del Bo et al.,
1995; Giulian et al., 1995; Klegeris et al., 1997; Combs et al., 1999,
2000, 2001a,b) have demonstrated robust microglial stimulation
by fibrillar forms of A, suggesting that peptide-mediated activa-
tion in vivo could be temporally or spatially unique, depending
upon what ligand the microglia are exposed to.
Although the infusion paradigm allowed us some ability to
examine oligomeric A as a stimulus, we are clearly not able to
discern what form of peptidemight be responsible for themicro-
gliosis observed in the APP/PS1 mouse brains. However, even if
some combination of peptide conformations or other stimuli in
the brain are ultimately responsible for the microglial activation
associated with these mice, reduced endogenous APP expression
was sufficient to attenuate microglial activation. More impor-
tantly, this correlated with reduced cytokine mRNA levels and
improved behavioral performance despite maintained overall
plaque load, although the ratio of 1-40/1-42 may have been al-
tered. This not only supported the idea that the inflammatory,
gliotic changes in the brain contribute to cognitive dysfunction in
disease but also that APP is an importantmodulator ofmicroglial
phenotype. We have previously reported a role for APP in mod-
ulating cell–cell adhesion, inflammatory response, and immune
cell phenotype in monocytes, endothelial cells, and enteric im-
mune systems (Sondag and Combs, 2004; Austin and Combs,
2010; Puig et al., 2012). Indeed, others have also demonstrated
that APP immunoreactivity increases inmicroglia in rodentmul-
tiple sclerosis models (Gehrmann et al., 1995; Ferguson et al.,
1997; Bitsch et al., 2000) or after traumatic brain injury (Sherriff
et al., 1994; Bramlett et al., 1997; Thornton et al., 2006; Corrigan
et al., 2011), suggesting that the protein does have a role in mod-
ulating the phenotype of these cells. We appreciate that loss of
rodent A in parallel with loss of APP and other proteolytic frag-
ments may also have contributed to the changes we observed.
Indeed, although increased rodent A production does not ap-
pear to promote plaque deposition or gliosis, it has been reported
to alter human A solubility and localization in transgenic mice
(Jankowsky et al., 2007). Even though the specificmechanisms by
which APP or any of its multiple metabolites regulate microglial
activation in AD has not yet been resolved in either our study or
prior work, further dissection of the role of APP in these immune
cells will help define this. Indeed, prior work from other groups
supports the idea that APP has a critical role in regulating overall
immune phenotype (Grant et al., 2012; Kurnellas et al., 2014,
2015; Steinman et al., 2014). Perhapsmost relevant to the current
study is a recent publication by Carrano and Das (2015) dem-
onstrating that APP knock-out microglia have attenuated cy-
tokine secretion and altered morphologic phenotype both in
vitro and in vivo in response to stimulation with LPS. This
demonstrates that the role of APP in regulating microglial
phenotype is likely much more complex than serving as a
putative receptor for A interaction.
Although the focus of this study has been on microglial A–
APP interaction, it is clear that multiple causes of microgliosis
may be relevant to AD and that APP is expressed by other cell
types in the brain. Even though the infusion data better supports
a role for APP in microgliosis with respect to specific oligomeric
A stimulation, the mice used in those experiments as well as in
our APP/PS1mAPP/ line lacked APP in all cell types. There-
fore, in the absence of a cell-specific APP deletion, we at this stage
interpret our findings to demonstrate that endogenous APP is
needed for robust microgliosis, behavioral, and cytokine changes
in the APP/PS1mice. It is interesting to speculate that oligomeric
A may also be able to interact with APP expressed on neurons
and astrocytes tomediate, for example, specific cellular responses
concomitant with any stimulation of microglia. Future effort in
this regard as well as cell-specific APP knockdown will better
resolve which cell types require APP expression in order for the
brain to mount the robust inflammatory, degenerative, and be-
havioral changes associated with AD.
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